Psychedelics: The pathway to implementation in the European healthcare systems.

Integrating psychedelic therapies into European healthcare requires not only European Medicines Agency (EMA) approval for safety, efficacy, and quality, but also positive Health Technology Assessment (HTA) evaluations from each member state, which assess added therapeutic value, cost-effectiveness, and societal impact. HTA bodies like the UK's NICE, Germany's IQWiG, and France's HAS often demand active comparator studies rather than placebo controls to demonstrate advantage over existing care—a major hurdle since such trials for psychedelic-assisted therapies are almost absent. The combination of psychedelics with psychotherapy further complicates evaluations, as few frameworks assess combination therapies. A standardized European HTA approach could promote equitable access across countries.

Study at a glance

Abstract

The integration of psychedelic therapies into European healthcare is a nuanced process that involves not only obtaining European Medicines Agency (EMA) approval but also successfully navigating Health Technology Assessment (HTA) evaluations across member states. After EMA approval, which focuses on the safety, efficacy, and quality of the therapeutic, HTA agencies assess these therapies for their "added therapeutic value," considering factors like cost-effectiveness, clinical outcomes, and overall societal impact. Each country's HTA, including the UK's National Institute for Health and Care Excellence (NICE), Germany's Institute for Quality and Efficiency in Health Care (IQWiG), and France's Haute Autorité de Santé (HAS), plays a pivotal role in determining reimbursement and access to these treatments. An added challenge is that HTA bodies in Europe often require active comparator studies rather than just placebo controls to establish a treatment's advantage over existing standard of care - a particular hurdle for psychedelic-assisted therapies, where controlled trials against active comparators are almost completely lacking. Furthermore, psychedelics are typically integrated with psychotherapy, adding complexity to HTA evaluations, as few frameworks currently assess the value of combination therapies within healthcare systems. Creating a standardized HTA approach or a unified European guideline for such novel treatments could promote equitable access across countries, helping to overcome the discrepancies in market access and patient reach across Europe.